AEON Biopharma, Inc.
AEON · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 1.07 | 0.69 | -0.10 |
| FCF Yield | -96.59% | -0.12% | -17.74% | -14.13% |
| EV / EBITDA | -1.22 | -757.52 | -6.70 | -7.70 |
| Quality | ||||
| ROIC | -670.45% | 5,873.88% | 7,195.99% | -5,331.74% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.48 | 0.12 | 0.68 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 57.57% | -33.25% | -25.48% | -202.33% |
| Safety | ||||
| Net Debt / EBITDA | -0.47 | 0.09 | -2.52 | -2.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -12,491.11 | 0.00 | 0.00 |